Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Mar 18;11:630825. doi: 10.3389/fphar.2020.630825

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ze Peng 1,†, Wen Wen Wu 2,†, Ping Yi 3,*
PMCID: PMC8012535  PMID: 33815097

Abstract

Background: For advanced non-small cell lung cancer (NSCLC) patients, first-line chemotherapy is the main treatment in the clinic despite its efficacy is limited and adverse effects are always inescapable. Ginsenoside Rg3, an anti-cancer active ingredient by suppressing angiogenesis, has been increasingly widely used as an adjuvant in first-line chemotherapy for advanced NSCLC to optimize treatment in China. However, no comprehensive meta-analyses have been conducted to estimate the efficacy and safety of the therapy combining ginsenoside Rg3 and first-line chemotherapy in advanced NSCLC patients.

Methods: Randomized controlled trails using a combination of first-line chemotherapy and ginsenoside Rg3 for advanced NSCLC patients were searched and selected from six databases. The Cochrane Risk of Bias tool was used to assessed the quality of these selected original researches. And we used Review Manager 5.3 and STATA to analyze the data.

Results: Twenty-two RCTs that matched our selection criteria with a number of 2202 patients were included in our review. The results showed that compared with first-line chemotherapy alone, the combination of ginsenoside Rg3 and first-line chemotherapy could better improve the objective response rate (ORR) (RR [95% CI], 1.44 [1.27, 1.63], p < 0.00001 ), the disease control rate (DCR) (RR [95% CI], 1.24 [1.12, 1.38], p < 0.0001), karnofsky performance status (KPS) (RR [95% CI], 1.62 [1.42, 1.84], p < 0.00001), one-year survival rate (RR [95% CI], 1.49 [1.08, 2.06], p = 0.01), two-year survival rate (RR [95% CI], 6.22 [1.68, 22.95], p = 0.006), weight change (RR [95% CI], 1.31 [1.04, 1.66], p = 0.02), and higher reduce the VEGF levels (RR [95% CI], -2.21 [-4.03, -0.38], p = 0.02), the incidence of gastrointestinal reactions (RR [95% CI], 0.66 [0.47, 0.93], p = 0.02) and bone marrow suppression (RR [95% CI], 0.43 [0.30, 0.61], p < 0.00001).

Conclusion: Ginsenoside Rg3 can enhance drug efficacy and reduce drug-induced toxicity from chemotherapy. These findings provide helpful information for clinicians indicating that a therapy combined of ginsenoside Rg3 and first-line chemotherapy may be used to optimal the treatment of advanced NSCLC.

Keywords: Ginsenoside Rg3, advanced non-small cell lung cancer, first-line chemotherapy, meta-analysis, systematic review

Introduction

As a serious health issue all over the world, lung cancer has the highest morbidity and mortality in all cancers (Siegel et al., 2020). Approximately 85% of patients with lung cancer have a group of histological subtypes that are collectively known as non-small cell lung cancer (NSCLC) (Herbst et al.,2018). Since the majority of patients with NSCLC are diagnosed at an advanced stage (III or IV) when the cancer cells have usually metastasized (Du and Morgensztern 2015), most of them unfortunately lose the opportunity for surgical treatment. Only 18% of patients with advanced NSCLC undergo surgery, and nearly 62% advanced patients with NSCLC are treated with radiation treatment and systemic treatment including chemotherapy, targeted therapy and immunotherapy to improve long-term survival rate (Miller et al., 2019). Although in the past several years, great progress has been significantly made in molecularly targeted therapy and immunotherapy, first-line chemotherapy remains a mainstay in the therapeutic management of NSCLC (Rossi and Di, 2016; Nasim et al., 2019). Particularly, platinum-based regimens are the most active combinations in clinical practice and show a meaningful clinical benefit for advanced NSCLC patients (Watanabe et al., 2017; Herbst et al.,2018).

However, although platinum-based regimens show several benefits for patients with advanced NSCLC, only a minority of patients indeed achieve an objective treatment response and the 5-year survival rate is still less than 20% (Rose et al., 2014). Moreover, it cannot be ignored that chemotherapy drugs often lead to severe side effects, such as bone marrow suppression, serious gastrointestinal reaction and liver abnormalities (Islam et al.,2019; von Plessen, 2011). And another limitation of first-line chemotherapy is the increasing ineffectiveness of chemotherapy caused by drug resistance. It’s reported that the drug resistance induced by platinum-based chemotherapies can be as high as 70% in advanced NSCLC patients (Rossi and Di Maio, 2016; Zhao and Chen, 2020). Therefore, looking for optimal therapy which can improve the efficacy of chemotherapy and reduce the incidence of side effects is of great necessity.

In recent years, traditional Chinese medicine (TCM) has played an increasingly important role in anti-cancer for its efficacy and security (Xiang et al., 2019). The combination of Chinese and Western therapy in anti-cancer treatment has become a hot trend all over the world (Liao et al., 2017; So et al., 2019). Ginseng, as a famous Chinese herbal medicine, has a medicinal history of four thousand years in China and is well known as ‘the king of herbs’ (Wang and Jin, 2018). Ginsenoside Rg3, a naturally active ingredient extracted from ginseng leachate, has been showed to possess anti-cancer in various tumors, especially in advanced NSCLC (Li Y et al., 2016). The therapeutic effects of ginsenoside Rg3 include inducing tumor apoptosis, inhibiting tumor metastasis, suppressing tumor angiogenesis and reversing drug resistance (Luo et al., 2019; Nakhjavani et al., 2020). In addition, there is a synergistic effect when ginsenoside Rg3 is used in combination with chemotherapy drugs (Sun et al., 2017; Wang and Jin, 2018; Zhao and Chen, 2020). Nowadays, an increasing number of studies have indicated that ginsenoside Rg3 may be a widely applied natural medicine in the treatment of NSCLC (Gao and Liu, 2019) and its combination with first-line chemotherapy drugs may brings great promise to the management of advanced NSCLC.

At present, some clinical trials of ginsenoside Rg3 combined with first-line chemotherapy on NSCLC have been conducted in China. However, no comprehensive meta-analyses have been conducted to estimate the efficacy and safety of this combination therapy. The purpose of this systematic review and meta-analysis is to evaluate the efficacy and safety of the therapy combining ginsenoside Rg3 and first-line chemotherapy in advanced NSCLC.

Materials and Methods

Search Strategy

A systematic literature search for RCTs testing the combination of ginsenoside Rg3 and first-line chemotherapy in advanced NSCLC published from the inception of each database to October 2020 was conducted without language restrictions in six databases, including PubMed, Web of Science, the Cochrane Library, Wan Fang Database, Chinese VIP Information (VIP) and China National Knowledge Infrastructure (CNKI).

A free term strategy was used, for Chinese databases, the following terms were used in combined ways: “Renshen zao gan Rg3 or Shenyi jiaonang” and “feixiao xibao feiai”; for English databases, we used text terms including “ginsenoside Rg3 or Shenyi capsule” and “NSCLC”.

Selection Criteria

The inclusion criteria were as follows: 1) patients: age of ≥18 years, histological or cytological confirmation of advanced NSCLC. 2) interventions: the control group were treated with first-line chemotherapy and the combination of ginsenoside Rg3 and first-line chemotherapy was conducted in the experiment group relatively. 3) the outcome should include at least one of the following indicators: objective response rate, disease control rate, Karnofsky`s performance score (KPS) and adverse effects. 4) study design: randomized clinical trials (RCTs).

The exclusion criteria were as follows: 1) non-RCTs including case reports, reviews, animal or cell studies and studies without a control group. 2) patients treated with other therapies, expect for ginsenoside Rg3 and chemotherapy. 3) patients with small cell lung cancer (SCLC) or other serious diseases. 4) early NSCLC.

Data Extraction

Two independent reviewers (Ze Peng and Wen Wen Wu) extracted the data according to the inclusion criteria. The characteristics of the data consisted of the author, publication year, the number and sex of participants, interventions, treatment cycles, the stage of NSCLC and outcomes. Where outcomes were ambiguous or missing in an article, the decision to retrieve from that article was resolved by consensus.

Methodological Quality

The Cochrane Risk of Bias tool was used to assessed the quality of the literature by two reviewers (Ze Peng and Wen Wen Wu) separately. The assessed items included: 1) random sequence and allocation concealment; 2) blinding of participants and personnel; 3) blinding of outcome assessment; 4) incomplete outcome data; 5) selective reporting; 6) other bias. For any disagreement, the risk of bias was discussed by consensus.

Data Synthesis and Analysis

We performed the analysis by using Review Manager (ver. 5.3) and STATA (ver.14) software. For binary variables, the risk ratio (RR) with 95% confidence interval (CI) was used to evaluate the pool effects. p value <0.05 was considered statistically significant. We used Chi-squared and I2 tests to evaluate the heterogeneity of all studies included. The fixed-effect model was selected for analysis with p > 0.05 or I2 < 50%; otherwise, we choose the random-effect model. And we assessed the sensitivity analysis to state the effect of changing the study model on the pooled analysis results. Begg’s tests were carried out to determine the publication biases and p value >0.05 was considered as no publication bias.

Results

Study Inclusions

A total of 360 studies were identified through systematic search, which included 190 repeated records (Figure 1). After a first screening, 36 were included by browsing the titles and abstracts of the remaining 170 studies. Then the remaining studies were further carefully scrutinized, and 134 articles were eliminated due to animals or cell experiments (n = 19), review (n = 16) and other therapies consisting of radiotherapy, postoperative lung cancer, and maintenance therapy (n = 99). Finally, excluding the studies with no control group or non-first-line chemotherapy regimens, 22 articles were included in this systematic analysis (Chen and Li 2012; Chen et al., 2014; Du 2014; Li and Bai 2017; Li et al., 2012; Liang and Han 2016; Lin et al., 2014; Liu et al., 2007; Liu et al. 2009; Liu et al. 2015; Pan and Wu, 2016; Pan et al., 2019; Pang, 2012; Qi and Zhang 2011; Shen et al., 2018; Sun et al., 2006; Tu, 2008; Wang et al., 2020; Wang et al., 2011; Wang et al., 2017; Zhang et al., 2020; Zhang et al., 2018).

FIGURE 1.

FIGURE 1

Open in a new tab

Flow chart of study selection process.

Characteristics of the Studies

Twenty-two studies with 2202 patients were included in our review. All RCTs originated from China and were published in Chinese journals. The year of publication was between 2006 and 2020, with 19 studies from the last decade. The patients’ characteristics of included studies included age, gender, clinical stage, chemotherapy regimen, and treatment indicators and were summarized in Table 1.

TABLE 1.

Characteristics of RCTs included in the study.

Study Sample size(E/C) Age Sex(Man/Feman) Clinical stage Pathological type Experiment Group(E) Control Group(C) Treatment Cycle First Treatment Outcome
Chen and Li (2012) 35/35 55.5/60.5 24/11; III 14,IV 21; S20,A15; Rg3 20 mg GP 6-9 weeks NO Efficac ( RECIST ); Adverse reactions; KPS
22/13 III 13,IV 22 S18,A17 po.bid +C
Chen et al. (2014) 34/34 4 1 ∼ 7 3 39/29 IIIB-IV A26,S21,AC18,B3 Rg3 20 mg TP 12 weeks No Efficacy(RECIST); Adverse reactions; Immune index
po.bid +C
Du (2014) 30/30 40.2 ± 3.6 31/29 advanced NSCLC Rg3 20 mg TP 6 weeks No Efficacy(RECIST);KPS
po.bid +C
Li and Bai (2017) 90/90 57 ± 1. 3/58 ± 1. 0 49/41; advanced NSCLC Rg3 20 mg GP 9 weeks No Efficacy(RECIST); PFS,OS; Adverse reactions
49/41 po.bid +C
Li et al. (2012) 39/38 - - advanced A23,S14,B2;A20,S16,B2 Rg3 20 mg GP 6 weeks No Efficacy(RECIST); KPS;Adverse reactions PFS;one-year survival rate
po.bid +C
Liang and Han (2016) 47/46 67.47 ± 7.74/66. 32 ± 6. 21 34/13; IIIA-IV NSCLC Rg3 20 mg GP 12 weeks No KPS;Adverse reactions
31/15 po.bid +C
Lin et al. (2014) 33/25 65-85 32/26 IIIA6,IIIB6,IV46 A44,S8,P6 Rg3 20 mg PC 6 weeks No Efficacy(RECIST); KPS;Adverse reactions
po.bid +C
Liu et al. (2007) 35/35 35-70 43/27 IIIB-IV S26,A40,B4 Rg3 20 mg NP 6 weeks Yes Efficacy(WHO); KPS;Adverse reactions;Immune index
po.bid +C
Liu et al. (2009) 34/30 43-75/31-66 26/8;19/11 IIIB22,IV12/IIIB26,IV4 A21,S9,AC4/A21,S6,AC2,B1 Rg3 20 mg NP 6 weeks No Efficacy(WHO);Adverse reactions;one-year survival rate
po.bid +C
Liu et al. (2015) 60/60 52.5 ± 2.0/54.6 ± 2.1 46/14;35/25 III37,IV23/III29,IV31 A19,S41/A13,S46 Rg3 20 mg NP - No Efficacy(unclear);Adverse reactions
po.bid +C
Pan and Wu (2016) 24/24 71.5/71 16/8;15/9 advanced unclear Rg3 20 mg TP 6 weeks No Efficacy(RECIST); KPS;Adverse reactions
po.bid +C
Pan et al. (2019) 103/104 60.6 ± 10.4/62.5 ± 11.9 53/50;51/53 III-IV unclear Rg3 20 mg TP 9 weeks Yes Efficacy(RECIST); KPS;Immune index
po.bid +C
Pang (2012) 22/21 63.95 26/17 IIIB13,IV30 A26,S18 Rg3 20 mg GP/PC/TP 6 weeks Yes Efficacy(RECIST); KPS;Adverse reactions
po.bid +C
Qi and Zhang (2011) 35/35 37-70 48/22 advanced A40,S26,B4 Rg3 20 mg GP 6 weeks Yes Efficacy(unclear); KPS;Adverse reactions
po.bid +C
Shen et al. (2018) 25/27 66-78/66-77 14/11;17/10 IIIB-IV A15,S10/A19,S8 Rg3 20 mg GP/PC 6 weeks Yes Efficacy(WHO); Adverse reactions;one-year survival rate
po.bid +C
Sun et al. (2006) 51/50 59.54/57.44 40/14;39/22 III21,IV33/III24,IV37 S16,A27,AC6,05;S13,A44,AC2,O2 Rg3 20 mg NP 6 weeks No Efficacy(WHO); Adverse reactions; PFS
po.bid +C
Tu (2018) 21/20 - 13/8;11/9 III7,IV14;III8,IV12 A10,S7,04;A9,S9,02 Rg3 20 mg TP 6 weeks Yes Efficacy(RECIST); KPS;VEGF
po.bid +C
Wang et al. (2020) 39/39 54.9 ± 8.1/55.6 ± 7.8 21/18;22/17 IIIB18,IV21;IIIB19,IV20 A20,S19;A21,S18 Rg3 20 mg GP/PC 6 weeks No Efficacy(WHO); Adverse reactions
po.bid +C
Wang et al. (2011) 59/58 53 74/43 IIIB-IV A31,S28/A37,S21 Rg3 20 mg GP/NP - Yes VEGF;KPS;Adverse reactions
po.bid +C
Wang et al. (2017) 45/44 58. 95 52/37 IIIb41,IV48 A58,S31 Rg3 20 mg TP/PC/GP/NP 6 weeks No Efficacy(unclear);KPS;Adverse reactions
po.bid +C
Zhang et al. (2020) 41/41 71. 34 ± 4. 25/71. 52 ± 3. 65 27/14;26/15 IIIb18,IV23/IIIb17,IV24 UNCLEAR Rg3 20 mg GP 12 weeks No Efficacy(WHO);KPS;Immune index; Adverse reactions
po.bid +C
Zhang et al. (2018) 199/215 61.16 ± 10.41/60.76 ± 10.39 128/71;161,64 IIIA25,IIIB74,IV100/IIIA20,IIIB73,IV122 A114,S65,B3,017/A121,S72,B3,O19 Rg3 20 mg NP/TP ≥6 weeks Yes Adverse reactions
po.bid +C
Open in a new tab

S, squamous cell carcinoma; A, adenocarcinoma; AC, adenosquamous carcinoma; B, large cell carcinoma; O, poorly differentiated carcinoma; GP, gemcitabine; TP, PTX; PC, pemetrexeddisodium; NP, navelbine.

Quality Assessment

Figure 2 showed our assessment of the bias risk of the included studies by Review Manger 5. All included studies described the process of random sequence generation. However, only 9 of the 22 studies described the detailed process of avoiding selection bias and just two studies reported the allocation concealment and blinding of outcome assessment in detail. As for the performance bias, only three studies mentioned and the rest were not. Among the included studies, three articles were identified as high risk of reporting bias for outcome because the disease control rate was not reported. Nevertheless, they included other important indicators to evaluate the efficacy and safety of ginsenoside Rg3 in combination with first-line chemotherapy in advanced NSCLC, such as KPS, weight change, and side effects. Therefore, after our discussion, we decided to include these three studies in this analysis. The results of each study were reported faithfully, therefore we considered all studies to be free of reporting bias (Figures 2, 3).

FIGURE 2.

FIGURE 2

Open in a new tab

Risk of bias.

FIGURE 3.

FIGURE 3

Open in a new tab

Risk of bias summary.

Tumor Response

Nineteen studies with 1470 advanced NSCLC participants recorded the short-term treatment efficiency of ginsenoside Rg3 combined with first-line chemotherapy. The overall heterogeneity of the meta-analysis showed that the included studies had clinical and statistical homogeneity, so a fixed-effect model was chosen. As illustrated in Figure 4, the experimental group had a higher objective response rate (ORR) than the control group (RR [95% CI], 1.44 [1.27, 1.63], p < 0.00001). For disease control rate (DCR), heterogeneity test (I2 = 77%) suggested that there was considerable heterogeneity, so we turned to a random effect model. Compared with chemotherapy alone, the combine of ginsenoside Rg3 and chemotherapy had a better effect on DCR (RR [95% CI], 1.24 [1.12, 1.38], p < 0.0001) (Figure 5). Subsequently, we performed regression analysis and subgroup analysis, suggesting that there was no difference in year of publication, evaluation criteria, chemotherapy drugs and first treatment (Supplementary Figures S1, S2).

FIGURE 4.

FIGURE 4

Open in a new tab

The pooled effects of ginsenosides Rg3-containing chemotherapy on objective response rate.

FIGURE 5.

FIGURE 5

Open in a new tab

The pooled effects of ginsenosides Rg3-containing chemotherapy on disease control rate.

Quality of Life

Karnofsky performance status (KPS) score was used to evaluate quality of life. Fourteen of the twenty-two studies evaluated the effect of ginsenoside Rg3 combined with chemotherapy on quality of life in patients with advanced NSCLC (Figure 6). An increased of 10 or more in KPS score after treatment was considered as a significant improvement in quality of life, otherwise, it was considered as a stable or even deteriorating quality of life. There was no clinically and statistically significant heterogeneity in these trials. For KPS increase rate, the experimental group was significantly higher than the control group (RR [95% CI], 1.62 [1.42, 1.84], p < 0.00001). As for KPS stability rate, the experimental group was higher when compared with the control group (RR [95% CI], 1.21 [1.08, 1.36], p = 0.001) (Supplementary Figure S3).

FIGURE 6.

FIGURE 6

Open in a new tab

The pooled effects of ginsenosides Rg3-containing chemotherapy on KPS.

Year Survival Rate

For patients with advanced NSCLC, survival rate is an important parameter to evaluate the therapeutic effect. A fixed-effect model was chosen because of the low heterogeneity. Three articles reported one-year survival rate, the results showed that ginsenoside Rg3 combined with chemotherapy had a higher one-year survival rate than chemotherapy alone (RR [95% CI], 1.49 [1.08, 2.06], p = 0.01) (Figure 7). Two studies reported two-year survival rate, the results showed that ginsenoside Rg3 combined with chemotherapy group had a higher two-year survival rate than chemotherapy alone group (RR [95% CI], 6.22 [1.68, 22.95], p = 0.006) (Figure 8).

FIGURE 7.

FIGURE 7

Open in a new tab

The pooled effects of ginsenosides Rg3-containing chemotherapy on one-year survival rate.

FIGURE 8.

FIGURE 8

Open in a new tab

The pooled effects of ginsenosides Rg3-containing chemotherapy on two-year survival rate.

Weight Change

A total number of five studies reported changes in body weight before and after treatment, and weight gain of ≥1 kg was defined as weight improvement. Compared with the control group, the experimental group had a higher rate of weight improvement. (RR [95% CI], 1.31 [1.04, 1.66], p = 0.02) (Supplementary Figure S4).

VEGF Leaves

Four articles reported the changes in serum VEGF levels before and after chemotherapy. Because of the high heterogeneity, we chose the random effect model. The experimental group could reduce the level of VEGF more effectively after treatment compared to the control group (RR [95% CI], −2.21 [−4.03, −0.38], p = 0.02) (Supplementary Figure S5).

Side Effects

The side effects of chemotherapy mainly include gastrointestinal reactions, liver and kidney injury, bone marrow suppression, and hematological toxicity. The incidence of liver and kidney dysfunction (RR [95% CI], 0.72 [0.52, 1.00], p = 0.05) and hematotoxicity (thrombocytopenia: RR [95% CI], 0.64 [0.33, 1.22], p = 0.17; leukopenia: RR [95% CI], 0.82 [0.66, 1.02], p = 0.07; hemoglobin reduction: RR [95% CI], 0.84 [0.60, 1.17], p = 0.29) in the experimental group was not statistically different compared with the control group (Supplementary Figures S6–S9). The experimental group had a lower incidence of gastrointestinal reactions compared to the control group (RR [95% CI], 0.66 [0.47, 0.93], p = 0.02) (Figure 9). Although some studies influenced the overall heterogeneity of this metric (I2 = 92%; p < 0.00001), the overall effects remained largely significant. In addition, six studies reported the occurrence of myelosuppression and showed that the experimental group had a lower incidence of myelosuppression than the control group (RR [95% CI], 0.43 [0.30, 0.61], p < 0.00001) , with no heterogeneity (I2 = 0%; p = 0.57) (Supplementary Figure S10).

FIGURE 9.

FIGURE 9

Open in a new tab

The pooled effects of ginsenosides Rg3-containing chemotherapy on gastrointestinal reactions.

According to WHO toxicity classification criteria, grade III-IV was defined as serious adverse reactions. The incidence of leukopenia in the experimental group was lower than that in the control group among the serious adverse reactions (RR [95% CI], 0.48 [0.34, 0.67], p < 0.001) (Supplementary Figure S11), and the remaining serious adverse reactions were not statistically different.

Publication Bias and Sensitivity Analysis

We performed publication bias analysis on the main parameters and the results showed that publication bias may have an impact on disease control rate and KPS (ORR: p = 0.555; DCR: p = 0.008; KPS: p = 0.015) (Figure 10). We conducted sensitivity analyses of the key effect indicators, including objective response rate, disease control rate, and KPS, and the results showed all to be authentic, verifiable, and of good stability (Figure 11).

FIGURE 10.

FIGURE 10

Open in a new tab

Begg`s regression analyses for publication bias. (A) Objective response rate; (B) Disease control rate; (C) KPS.

FIGURE 11.

FIGURE 11

Open in a new tab

Sensitivity analysis plots. (A) Objective response rate; (B) Disease control rate; (C) KPS.

Discussion

In recent years, the combination of ginsenoside Rg3 and chemotherapy has been increasingly proposed and conducted in advanced NSCLC. This systematic review and meta-analysis is the latest to evaluate the efficacy and safety of the therapy combining ginsenoside Rg3 and first-line chemotherapy in advanced NSCLC. The results showed that ginsenoside Rg3 in combination with first-line chemotherapy resulted in better objective response rate, disease control rate, KPS score and one-/two-year survival rate, higher increases in patients weight, and higher reduction in VEGF levels and side effects compared with chemotherapy alone.

According to the Response Evaluation Criteria in Solid Tumors (RECIST), assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials (Eisenhauer et al., 2009). ORR was defined as complete response (CR) or partial response (PR). Disease control rate (DCR)was defined as CR or PR in all patients or stable disease (SD) in patients with progressive disease (PD) at the treatment of chemotherapy. At the current time ORR carries with it a body of evidence greater than for any other biomarker supporting its utility as a measure of promising treatment effect in clinical trails.

In our study, 19 studies reported ORR and DCR. Consistent with previous meta-analysis, the results suggested that ginsenoside Rg3 in combination with chemotherapy had a significant advantage in improving ORR (RR 1.44) and DCR (RR 1.23). Subsequently, we classified the patients included in the study as whether they were receiving antineoplastic therapy for the first time. Subgroup analysis showed no statistical difference between the two groups, indicating that chemotherapy containing ginsenosides was significantly beneficial in improving ORR, regardless of whether the patient had received prior anticancer treatment. In addition, there are four main first-line chemotherapy drugs in clinical practice, namely gemcitabine (GP), paclitaxel (TP), norvinblastine (NP), and pemetrexide (PC). The results of subgroup analysis showed that ginsenoside combination chemotherapy improved ORR independent of the type of chemotherapeutic agent. The above results suggested us that ginsenoside Rg3 a broad application prospect in the clinical field.

KPS is the Karnofsky performance status scoring standard. The higher the score, the better you are and the more you can tolerate the side effects of treatment, therefore, NSCLC patients are likely to receive complete chemotherapy (Terret et al., 2011). Adding ginsenoside Rg3 to chemotherapy could effectively improve the quality of life of patients with advanced NSCLC and reduce the suffering caused by the disease and chemotherapy (Lu et al., 2008). Previous meta-analysis had demonstrated that ginsenoside combined with chemotherapy could significantly increase KPS in patients with NSCLC (Xu et al., 2016). In our analysis, summary estimates of 14 trials also showed a significant improvement of KPS in the treatment group compared with control group, the improvement was statistically significant. In addition, for the first time, we included weight change as an indicator, which is also important for assessing quality of life. Our results showed that ginsenoside Rg3 combined with chemotherapy was effective in increasing the weight of NSCLC patients (p = 0.02).

Annual survival rate is an important parameter to evaluate the prognosis of patients with advanced cancer. Ginseng itself has anti-cancer properties and health benefits, which has been used for centuries in Oriental medicine as a panacea to promote longevity (Kiefer and Pantuso, 2003; Wang et al., 2016). In our analysis, one-year survival and two-year survival rates were reported for the first time. The results showed that ginsenoside Rg3 combined with chemotherapy significantly improved survival time in patients with advanced NSCLC compared with chemotherapy alone. Unfortunately, the credibility of the evidence was relatively low due to the paucity of literature, and more data were needed to support this conclusion.

The vascular endothelial growth factor A (usually referred to as VEGF) play a central role in angiogenesis, promoting endothelial cell proliferation, migration and invasion. Recent evidence shows that VEGF directly targets tumor cells contributing to cancer growth and metastasis. High VEGF expression has been described in lung cancer (Frezzetti et al., 2017). Ginsenoside Rg3 has anti-angiogenic effects, which may be related to the fact that ginsenoside Rg3 reduces the expression of genes related to vascular genetics (Tang et al., 2018). In agreement with the previous meta-analysis, ginsenoside Rg3 combined with chemotherapy could effectively reduce VEGF levels in serum of advanced NSCLC patients (p = 0.02).

Systemic chemotherapy typically has very limited efficacy, along with severe systemic adverse effects, such as gastrointestinal reactions, hematological toxicity, liver and kidney injury and so on, which severely affect NSCLC patients' quality of life (Mangal et al., 2017; Islam et al., 2019). Patients with advanced NSCLC are usually forced to interrupt treatment because they can not tolerate the severe side effects, which greatly reduces the treatment outcome. Compared to the previous study (Xu et al., 2016), our article provided a comprehensive analysis of the side effects, and the results suggested that ginsenoside Rg3 combined with chemotherapy was effective in reducing the incidence of gastrointestinal reactions and also played a certain role in reducing other side effects, although there was no statistical difference. In conclusion, ginsenoside Rg3 was safe and effective as an adjuvant for chemotherapy.

Recently, many researchers had conducted in vitro experiments on the anti-NSCLC effects of ginsenoside Rg3. Liu et al. (2019) Reported that ginsenoside Rg3 could upregulate VRK1 expression and P53BP1 foci formation in response to DNA damage, thereby inhibiting the tumorigenesis and viability of cancer cells. Futhermore, ginsenoside Rg3 could enhance the anticancer activity of Gefitinib through increasing apoptosis and decreasing migration in NSCLC cell lines (Dai et al., 2019). Therefore, ginsenoside Rg3 can effectively improve the efficacy and reverse drug resistance, suggesting that it can be used as an adjuvant in clinical treatment to benefit NSCLC patients.

Limitations

Several limitations are worthy of discussion; firstly, the participants in the selected researches were all Chinese which may not be sufficiently representative. More studies with diverse populations are looking forward to validate the generalizability of our findings. Secondly, the blinded presentation of some studies is too simple or even missing, thus affecting the overall quality of the literature. Therefore, we may need more rigorous clinical experimental design to evaluate the efficacy and safety of ginsenoside Rg3 combined with chemotherapy for advanced NSCLC patients in the future. Thirdly, as an important parameter for evaluating the prognosis of patients with advanced NSCLC, the 5-year survival rate was missing in the original studies we analyzed. However, these studies reported 1-year and 2-year survival rate, both of which are important prognostic evaluation indicators for patients with advanced NSCLC as well. Finally, the sample size of articles screened in this study was not large enough due to the limited number of studies on the combination of chemotherapy and ginsenoside Rg3. More studies with high quality are expected to further validate the efficacy and safety of ginsenoside Rg3 in combination with first-line chemotherapy in advanced NSCLC.

Conclusion

Ginsenoside Rg3 can enhance drug efficacy and reduce drug-induced toxicity from chemotherapy. The efficacy and safety of ginsenoside Rg3 in combination with first-line chemotherapy was superior to that of single chemotherapy in patients with advanced NSCLC. These findings provide helpful information for clinicians, indicating that ginsenoside Rg3 can be used as an adjuvant to optimize the treatment of advanced NSCLC.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author Contributions

PY designed the study. ZP and WW conducted the experiments and wrote the manuscript.

Funding

This article was supported by the National Natural Science Foundation of China (No.81673757).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.630825/full#supplementary-material.

Click here for additional data file. (5.8MB, docx)

References

  1. Ando K., Kishino Y., Homma T., Kusumoto S., Yamaoka T., Tanaka A., et al. (2020). Nivolumab plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis. Cancers 12, 1905. 10.3390/cancers12071905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chen S., and Li R. (2012). Clinical observation of Shenyi capsule combined with GP regimen in the treatment of advanced non-small cell lung cancer. Contemp. Med. 31, 1. 10.3969/j.issn.1009-4393.2012 [DOI] [Google Scholar]
  3. Chen W., Tian Yi, Shi Y. (2014). Observation on the efficacy of integrated traditional Chinese and western medicine in the treatment of advanced non-small cell lung cancer. Mod. J. Integrated Tradit. Chin. West. Med. 23 (8), 880–881. 10.3969/j.issn.1008-8849.2014.08.037 [DOI] [Google Scholar]
  4. Chinese Medical Association (2020). Chinese medical association guidelines for clinical diagnosis and treatment of lung cancer (2019 edition). Zhonghua Zhong Liu Za Zhi 42 (4), 257–287. 10.3760/cma.j.cn112152-20200120-00049 [DOI] [PubMed] [Google Scholar]
  5. Dai Y., Wang W., Sun Q., Tuohayi J. (2019). Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines. Exp. Ther. Med. 17 (1), 953–959. 10.3892/etm.2018.7001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Du L. (2014). Clinical observation of Shenyi capsule in adjuvant treatment of advanced non-small cell lung cancer. J. Inner Mongolia Tradit. Chin. Med. 33 (34), 7. 10.3969/j.issn.1006-0979.2014.34.007 [DOI] [Google Scholar]
  7. Du L., Morgensztern D. (2015). Chemotherapy for advanced-stage non-small cell lung cancer. Cancer J. 21 (5), 366–370. 10.1097/PPO.0000000000000141 [DOI] [PubMed] [Google Scholar]
  8. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2), 228–247. 10.1016/j.ejca.2008.10.026 [DOI] [PubMed] [Google Scholar]
  9. Ettinger D. S., Wood D. E., Aggarwal C., Aisner D. L., Akerley W., Bauman J. R., et al. (2019). NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J. Natl. Compr. Cancer Netw. 17 (12), 1464–1472. 10.6004/jnccn.2019.0059.PMID:31805526 [DOI] [PubMed] [Google Scholar]
  10. Frezzetti D., Gallo M., Maiello M. R., D’Alessio A., Esposito C., Chicchinelli N., et al. (2017). VEGF as a potential target in lung cancer. Expert Opin. Ther. Targets 21, 959–966. 10.1080/14728222.2017.1371137 [DOI] [PubMed] [Google Scholar]
  11. Gao P. X., Liu Y. (2019). A brief discussion on the anticancer research results of ginsenosides Rg3 and Rh2. Contemp. Med. 25 (26), 193–194. 10.3969/j.issn.1009-4393.2019.26.084 [DOI] [Google Scholar]
  12. Herbst R. S., Morgensztern D., Boshoff C. (2018). The biology and management of non-small cell lung cancer. Nature 553, 446–454. 10.1038/nature25183 [DOI] [PubMed] [Google Scholar]
  13. Islam K. M., Anggondowati T., Deviany P. E., Ryan J. E., Fetrick A., Bagenda D., et al. (2019). Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. BMC Cancer 19 (1), 835. 10.1186/s12885-019-6054-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kiefer D., Pantuso T. (2003). Panax ginseng. Am. Fam. Physician 68 (8), 1539–1542. [PubMed] [Google Scholar]
  15. Li C., Li Q., Xu J. (2012). Clinical observation of Shenyi capsule combined with GP regimen in the treatment of advanced non-small cell lung cancer. Cancer Res. Prev. Treat. 39 (9), 1125–1127. 10.3971/j.issn.1000-8578.2012.09.017 [DOI] [Google Scholar]
  16. Li Y., and Bai W. (2017). Efficacy analysis of Shenyi capsule combined with GP chemotherapy regimen in the treatment of non-small cell lung cancer. Liaoning J. Tradit. Chin. Med. 44 (3), 553–555. 10.13192/j.issn.1000-1719.2017.03.037 [DOI] [Google Scholar]
  17. Li Y., Wang Y., Niu K., Chen X., Xia L., Lu D., et al. (2016). Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget 7 (43), 70535–70545. 10.18632/oncotarget.12059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liang J., Han X. (2016). The effect of ginsenoside Rg3 combined with chemotherapy on serum TGF-α, TGF-β1 and VEGF in patients with advanced non-small cell lung cancer. J. Clin. Pulm. Med. 21 (9), 1675–1678. 10.3969/j.issn.1009-6663.2016.09.035 [DOI] [Google Scholar]
  19. Liao Y. H., Li C. I., Lin C. C., Lin J. G., Chiang J. H., Li T. C. (2017). Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J. Cancer Res. Clin. Oncol. 143 (12), 2425–2435. 10.1007/s00432-017-2491-6 [DOI] [PubMed] [Google Scholar]
  20. Lin Q., Shen D., Lu C. (2014). Clinical observation of pemetrexed combined with shenyi capsule in the treatment of NSCLC. Med. Inf. 27 (24), 167–168. 10.3969/j.issn.1006-1959.2014.24.183 [DOI] [Google Scholar]
  21. Liu S., Sun L., Ban L. (2007). Clinical observation of Shenyi capsule combined with NP regimen in the treatment of advanced non-small cell lung cancer. J. Clin. Oncol. 12 (11), 847–849. 10.3969/j.issn.1009-0460.2007.11.014 [DOI] [Google Scholar]
  22. Liu X., Yang H., Li L. (2009). Observation on the efficacy of Shenyi capsule combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Jilin Med. 30 (19), 2319–2320. 10.3969/j.issn.1004-0412.2009.19.064 [DOI] [Google Scholar]
  23. Liu S., Zheng R., Cui J. (2015). Clinical study of Shenyi capsule combined with first-line chemotherapy in the treatment of advanced non-small cell lung cancer. Electron. J. Clin. Med. Lit. (24), 5040–5041. 10.16281/j.cnki.jocml.2015.24.073 [DOI] [Google Scholar]
  24. Liu T., Zuo L., Guo D., Chai X., Xu J., Cui Z., et al. (2019). Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. Biomed. Pharmacother. 120, 109483. 10.1016/j.biopha.2019.109483 [DOI] [PubMed] [Google Scholar]
  25. Lu P., Su W., Miao Z. H., Niu H. R., Liu J., Hua Q. L. (2008). Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin. J. Integr. Med. 14, 33–36. 10.1007/s11655-007-9002 [DOI] [PubMed] [Google Scholar]
  26. Luo H., Vong C. T., Chen H., Gao Y., Lyu P., Qiu L., et al. (2019). Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin. Med. 14, 48. 10.1186/s13020-019-0270-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mangal S, Gao W, Li T, Zhou Q. T. (2017). Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol. Sin. 38 (6), 782–797. 10.1038/aps.2017.34.Epub2017May1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Miller K. D., Nogueira L., Mariotto A. B., Rowland J. H., Yabroff K. R., Alfano C. M., et al. (2019). Cancer treatment and survivorship statistics, CA Cancer J. Clin. 69 (5), 363–385. 10.3322/caac.21565 [DOI] [PubMed] [Google Scholar]
  29. Nakhjavani M., Smith E., Townsend A. R., Price T. J., Hardingham J. E. (2020). Anti-angiogenic properties of ginsenoside Rg3. Molecules 25 (21), E4905. 10.3390/molecules25214905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nasim F., Sabath B. F., Eapen G. A. Lung cancer (2019). Med. Clin. North Am. 103, 463–473. 10.1016/j.mcna.2018.12.006 [DOI] [PubMed] [Google Scholar]
  31. Pan Y., Sun M., Liu X. (2019). The effect of Shenyi capsule on the chemotherapy effect of patients with advanced non-small cell lung cancer. Med. Clin. Res. 36 (10), 2043–2044. 10.3969/j.issn.1671-7171.2019.10.063 [DOI] [Google Scholar]
  32. Pan Y., Wu X. (2016). Docetaxel and Shenyi capsule combined with cisplatin in the treatment of elderly non-small cell lung cancer. J. Pract. Med. 33 (8), 699–700. 10.14172/j.issn1671-4008.2016.08.012 [DOI] [Google Scholar]
  33. Pang M. (2012). Study on the correlation between the short-term efficacy of Shenyi capsule combined with chemotherapy in the treatment of advanced non-small cell lung cancer and the changes of serum VEGF and bFGF levels: Jinan: University of Jinan. [Google Scholar]
  34. Qi C., Zhang H. (2011). Clinical observation of traditional Chinese medicine vascular inhibitor ginsenoside Rg3 combined with GP regimen in the treatment of non-small cell lung cancer. J. Pract. Clin. Med. 15 (11), 121–122. 10.3969/j.issn.1672-2353.2011.11.043 [DOI] [Google Scholar]
  35. Rose M. C, Kostyanovskaya E, Huang R. S. (2014). Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Dev. Reprod. Biol. 12, 198–209. 10.1016/j.gpb.2014.10.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rossi A., Di Maio M. (2016). Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev. Anticancer Ther. 16, 653–660. 10.1586/14737140.2016.1170596 [DOI] [PubMed] [Google Scholar]
  37. Shen K., Zhou W., Ye Z. (2018). Efficacy observation of Shenyi capsule combined with chemotherapy regimen in the treatment of elderly advanced non-small cell lung cancer. J. Pract. Clin. Med. 22 (23), 123–124. 10.7619/jcmp.201823037 [DOI] [Google Scholar]
  38. Siegel R. L., Miller K. D., Jemal A. (2020). Cancer statistics. CA Cancer J. Clin. 70, 7–30. 10.3322/caac.21590 [DOI] [PubMed] [Google Scholar]
  39. So T. H., Chan S. K., Lee V. H., Chen B. Z., Kong F. M., Lao L. X. (2019). Chinese medicine in cancer treatment–how is it practised in the east and the west?. Clin. Oncol. 31 (8), 578–588. 10.1016/j.clon.2019.05.016 [DOI] [PubMed] [Google Scholar]
  40. Sun Y., Lin H., Zhu Y. (2006). A multicenter double-blind randomized clinical study report of vinorelbine combined with cisplatin (NP) plus Shenyi capsule or placebo in the treatment of advanced non-small cell lung cancer. Chin. J. Lung Cancer 9 (3), 254–258. [DOI] [PubMed] [Google Scholar]
  41. Sun M., Ye Y., Xiao L., Duan X., Zhang Y., Zhang H. (2017). Anticancer effects of ginsenoside Rg3 (review). Int. J. Mol. Med. 39, 507–518. 10.3892/ijmm.2017.2857 [DOI] [PubMed] [Google Scholar]
  42. Tang Y. C., Zhang Y., Zhou J., Zhi Q., Wu M. Y., Gong F. R., et al. (2018). Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo . Int. J. Oncol. 52 (1), 127–138. 10.3892/ijo.2017.4183.Epub2017Nov1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Terret C., Albrand G., Moncenix G., Droz J. P. (2011). Karnofsky performance scale (KPS) or physical performance test (PPT)? That is the question. Crit. Rev. Oncol. Hematol. 77, 142–147. 10.1016/j.critrevonc.2010.01.015 [DOI] [PubMed] [Google Scholar]
  44. Tu H. (2008). Effect of ginsenoside Rg3 combined with chemotherapy on serum vascular endothelial growth factor in patients with non-small cell lung cancer and observation of its efficacy: Fuzhou: Fujian University of Traditional Chinese Medicine. [Google Scholar]
  45. von Plessen C. (2011). Improving chemotherapy for patients with advanced non-small cell lung cancer. Clin. Respir. J. 5 (1), 60–61. 10.1111/j.1752-699X.2010.00199.x [DOI] [PubMed] [Google Scholar]
  46. Wang Y., Liu J., Zhao H. (2011). The efficacy of ginsenoside Rg3 capsule combined with chemotherapy in the treatment of advanced non-small cell lung cancer. J. Pract. Oncol. 25 (1), 33–35. 10.3969/j.issn.1002-3070.2011.01.010 [DOI] [Google Scholar]
  47. Wang C. Z., Anderson S., DU W., He T. C., Yuan C. S., (2016). Red ginseng and cancer treatment. Chin. J. Nat. Med. 14 (1), 7–16. 10.3724/SP.J.1009.2016.00007.PMID:26850342 [DOI] [PubMed] [Google Scholar]
  48. Wang G., Liu F., Zhang Z. (2017). Observation on the efficacy of Shenyi capsule combined with chemotherapy in the treatment of advanced non-small cell lung cancer and changes in serum MMP-9 and TIMP-1. Mod. Oncol. 25 (6), 896–901. 10.3969/j.issn.1672-4992.2017.06.015 [DOI] [Google Scholar]
  49. Wang F., Dai L., Shan S. (2020). Application of Shenyi capsule combined with chemotherapy in the treatment of advanced non-small cell lung cancer. China Healthcare Nutr. 30 (20), 319–320. [Google Scholar]
  50. Wang H. Y., Jin H. (2018). Research progress on anti-tumor effects of ginsenoside Rg3. Digest World Latest Med. Inf. 18 (68), 50–51. 10.19613/j.cnki.1671-3141.2018.68.022 [DOI] [Google Scholar]
  51. Watanabe S. I., Nakagawa K., Suzuki K., Takamochi K., Ito H., Okami J., et al. Group Lung Cancer Surgical Study, Group of the Japan Clinical Oncology (2017). Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer. Jpn. J. Clin. Oncol. 47 (12), 1112–1118. 10.1093/jjco/hyx147 [DOI] [PubMed] [Google Scholar]
  52. Xiang Y., Guo Z., Zhu P., Chen J., Huang Y. (2019). Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med. 8 (5), 1958–1975. 10.1002/cam4.2108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Xu T., Jin Z., Yuan Y., Wei H., Xu X., He S., et al. (2016). Ginsenoside Rg3 serves as an adjuvant chemotherapeutic agent and VEGF inhibitor in the treatment of non-small cell lung cancer: a meta-analysis and systematic review. Evid. Based Compl. Alternat. Med. 2016, 7826753. 10.1155/2016/7826753 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zhang Y., Wang X., Liu H. (2018). A multi-center large-sample randomized clinical study of Shenyi capsule combined with chemotherapy to improve the prognosis of patients with advanced non-small cell lung cancer. Chin. J. Oncol. 40 (4), 295–299. 10.3760/cma.j.issn.0253-3766.2018.04.011 [DOI] [PubMed] [Google Scholar]
  55. Zhang L., Huang L., Huang K. (2020). Shenyi capsule combined with chemotherapy on the short-term curative effect of patients with advanced non-small cell lung cancer and the effect of serum NKG2D, IFN-γ, IL-2 levels and T lymphocyte subsets. Chin. J. Gerontol. 40 (11), 2296–2299. 10.3969/j.issn.1005-9202.2020.11.017 [DOI] [Google Scholar]
  56. Zhao H., Chen J. H. (2020). Research progress in maintenance treatment of advanced non-small cell lung cancer. Oncol. Pharmacy. 10 (03), 269–274. 10.3969/j.issn.2095-1264.2020.03.03 [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (5.8MB, docx)

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES